Vigil Neuroscience (NASDAQ:VIGL) PT Raised to $23.00 at Wedbush

Vigil Neuroscience (NASDAQ:VIGL) had its price target increased by equities research analysts at Wedbush from $22.00 to $23.00 in a report issued on Friday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Wedbush’s target price suggests a potential upside of 475.00% from the company’s current price.

A number of other research firms have also recently weighed in on VIGL. JMP Securities reiterated a “market outperform” rating and set a $23.00 price target on shares of Vigil Neuroscience in a report on Thursday, April 18th. HC Wainwright reiterated a “buy” rating and set a $24.00 price target on shares of Vigil Neuroscience in a report on Friday.

Vigil Neuroscience Stock Down 10.7 %

Shares of VIGL opened at $4.00 on Friday. Vigil Neuroscience has a 52-week low of $2.47 and a 52-week high of $10.22. The company has a market capitalization of $150.32 million, a PE ratio of -1.89 and a beta of 1.94. The stock has a fifty day simple moving average of $3.51 and a two-hundred day simple moving average of $3.32.

Vigil Neuroscience (NASDAQ:VIGL) last issued its earnings results on Tuesday, May 7th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.10. As a group, equities analysts anticipate that Vigil Neuroscience will post -2.09 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Vigil Neuroscience

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in Vigil Neuroscience by 11.9% during the 1st quarter. Vanguard Group Inc. now owns 894,473 shares of the company’s stock valued at $3,050,000 after acquiring an additional 95,276 shares during the period. PEAK6 Investments LLC raised its position in Vigil Neuroscience by 66.0% in the 3rd quarter. PEAK6 Investments LLC now owns 23,796 shares of the company’s stock valued at $128,000 after purchasing an additional 9,459 shares in the last quarter. Finally, Strs Ohio acquired a new stake in Vigil Neuroscience in the 4th quarter valued at about $27,000. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.